pre-IPO PHARMA

COMPANY OVERVIEW

A fully integrated, global biotechnology company with the spirit of a start-up, Ichnos Sciences is shifting the way the world thinks about innovation in medicine through its research and development of transformative, disease-centric treatments in oncology, autoimmune disease and pain. The Company, with headquarters in Paramus, N.J., is rapidly advancing a clinical-stage pipeline of novel, first-in-class candidates designed to address complex diseases and treat patients holistically. With a patented BEAT® technology platform along with pioneering teams in Switzerland and India, Ichnos Sciences has a mission to provide breakthrough, curative therapies that will hopefully extend and improve lives, writing a new chapter in healthcare.


LOCATION

  • Paramus, NJ, USA
  • Epalinges, , Switzerland
  • La Chaux-de-Fonds, , Switzerland
  • Mumbai, Maharashtra, India

  • THERAPEUTIC AREAS

  • Autoimmune Disease
  • Oncology
  • Pain

  • WEBSITE

    https://www.ichnossciences.com


    CAREER WEBSITE

    None


    SOCIAL MEDIA


    INVESTORS



    PRESS RELEASES


    Jun 26, 2023

    ICHNOS SCIENCES WELCOMES LIDA PACAUD, M.D., AS NEW CHIEF MEDICAL OFFICER


    Mar 21, 2023

    ICHNOS SCIENCES RECEIVES ORPHAN DRUG DESIGNATION FOR FIRST-IN-CLASS BISPECIFIC (CD38 x CD47) ANTIBODY INNATE CELL MODULATOR, ISB 1442


    Dec 12, 2022

    ICHNOS SCIENCES PRESENTS DATA SUPPORTING THREE ONCOLOGY ASSETS AT ASH 2022 ANNUAL MEETING


    Nov 3, 2022

    ICHNOS SCIENCES DATA SELECTED FOR PRESENTATION AT THE 64TH ASH ANNUAL MEETING


    Sep 28, 2022

    ICHNOS SCIENCES ANNOUNCES INITIATION OF FIRST-IN-HUMAN STUDY FOR ISB 1442


    For More Press Releases


    Google Analytics Alternative